Status:
RECRUITING
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
University Hospital of North Norway
Haukeland University Hospital
Conditions:
Locally Advanced Pancreatic Cancer
Borderline Resectable Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who ...
Eligibility Criteria
Inclusion
- Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)
- Nx, M0 (UICC 8th version, 2016)
- Cytological or histological confirmation of adenocarcinoma
- Age \>18 year
- Considered able to receive primary chemotherapy and possible surgery
- Written informed consent
Exclusion
- Co-morbidity or performance status precluding primary chemotherapy
- Co-morbidity or performance status precluding pancreatectomy
- Female patients in child-bearing age not using adequate contraception, pregnant or lactating women
- Mental or physical disorders that could interfere with treatment of with the provision of informed consent
- Any reason why, in the opinion of the investigator, the patient should not participate
Key Trial Info
Start Date :
December 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06944587
Start Date
December 3 2024
End Date
December 31 2028
Last Update
April 25 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital
Bergen, Norway, Norway, 5021
2
Stavanger University Hospital
Stavanger, Norway, Norway, 4068
3
University Hospital of North Norway
Tromsø, Norway, Norway, 9038
4
St. Olavs Hospital, Trondheim University Hospital
Trondheim, Norway, Norway, 7006